Intermittent screening and treatment for malaria complementary to routine immunisation in the first year of life in Papua, Indonesia: a cluster randomised superiority trial

Intermittent screening and treatment for malaria complementary to routine immunisation in the first year of life in Papua, Indonesia: a cluster randomised superiority trial

Show other versions (1)

<strong>Background</strong> In Papua (Indonesia), infants with P. falciparum and/or P. vivax malaria are at risk of severe anaemia and death. We hypothesized that in an area of high malaria transmission, intermittent screening and treatment of infants with malaria (ISTi) will reduce morb...

Full description

Bibliographic Details
Main Authors:	Poespoprodjo, JR, Hafiidhaturrahmah, Sariyanti, N, Indrawanti, R, McLean, ARD, Simpson, JA, Kenangalem, E, Burdam, FH, Noviyanti, R, Trianty, L, Fadhilah, C, Soenarto, Y, Price, RN
Format:	Journal article
Language:	English
Published:	BioMed Central 2022

Similar Items

Intermittent screening and treatment for malaria complementary to routine immunisation in the first year of life in Papua, Indonesia: A cluster randomised superiority trial
by: Poespoprodjo, Jeanne Rini, et al.
Published: (2022)

Intermittent screening and treatment for malaria complementary to routine immunisation in the first year of life in Papua, Indonesia: a cluster randomised superiority trial
by: Jeanne Rini Poespoprodjo, et al.
Published: (2022-06-01)

Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial
by: Poespoprodjo, JR, et al.
Published: (2021)

Adherence to radical cure for Plasmodium vivax malaria in Papua, Indonesia
by: Rahmalia, A, et al.
Published: (2019)

Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life.
by: Burdam, F, et al.
Published: (2016)

Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study
by: Kenangalem, E, et al.
Published: (2019)

Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections
by: Pava, Z, et al.
Published: (2017)

Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia
by: Pava, Z, et al.
Published: (2016)

Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia
by: Pava, Z, et al.
Published: (2020)

Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study
by: Rahmalia, A, et al.
Published: (2023)

Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life.
by: Faustina Helena Burdam, et al.
Published: (2016-01-01)

Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study
by: Douglas, NM, et al.
Published: (2017)

Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections.
by: Zuleima Pava, et al.
Published: (2017-01-01)

Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: a rising burden of Plasmodium vivax malaria
by: Poespoprodjo, JR, et al.
Published: (2019)

Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia.
by: Zuleima Pava, et al.
Published: (2016-01-01)

The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study
by: Dini, S, et al.
Published: (2020)

The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia
by: Thriemer, K, et al.
Published: (2020)

High risk of Plasmodium vivax malaria following splenectomy in Papua, Indonesia
by: Kho, S, et al.
Published: (2018)

Malaria-related hospitalization during childhood in Papua, Indonesia: A retrospective cohort study
by: Douglas, NM, et al.
Published: (2020)

Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia
by: Setyadi, A, et al.
Published: (2019)

Early and late mortality after malaria in young children in Papua, Indonesia
by: Patriani, D, et al.
Published: (2019)

Treatment-seeking behavior after the implementation of a unified policy of dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua, Indonesia
by: Devine, A, et al.
Published: (2017)

Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia.
by: Zuleima Pava, et al.
Published: (2020-05-01)

Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study.
by: Enny Kenangalem, et al.
Published: (2019-05-01)

Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial
by: Poespoprodjo, Jeanne Rini, et al.
Published: (2022)

Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia.
by: Lampah, D, et al.
Published: (2015)

Passively versus actively detected malaria: similar genetic diversity but different complexity of infection
by: Pava, Z, et al.
Published: (2017)

Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study.
by: Douglas, N, et al.
Published: (2013)

Therapeutic response to Dihydroartemisinin-Piperaquine for P. falciparum and P. vivax nine years after its introduction in Southern Papua, Indonesia
by: Poespoprodjo, JR, et al.
Published: (2018)

Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study
by: Annisa Rahmalia, et al.
Published: (2023-05-01)

Characterization of blood dendritic and regulatory T cells in asymptomatic adults with sub-microscopic Plasmodium falciparum or Plasmodium vivax infection.
by: Kho, S, et al.
Published: (2016)

Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia
by: Karyana, M, et al.
Published: (2016)

The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.
by: Kamala Thriemer, et al.
Published: (2020-11-01)

Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia
by: Marfurt, J, et al.
Published: (2021)

Barriers to the success of COVID-19 immunisation programs in New Ireland Province, Papua New Guinea
by: Belinda Flanagan, et al.
Published: (2023-09-01)

Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia
by: Agus Setyadi, et al.
Published: (2019-04-01)

Severe malarial thrombocytopenia : a risk factor for mortality in Papua, Indonesia
by: Lampah, Daniel A., et al.
Published: (2015)

Malaria-related hospitalization during childhood in Papua, Indonesia: A retrospective cohort study.
by: Nicholas M Douglas, et al.
Published: (2020-01-01)

Early and late mortality after malaria in young children in Papua, Indonesia
by: Dewi Patriani, et al.
Published: (2019-10-01)

Increased circulating myeloid-derived suppressor cells in vivax malaria and severe falciparum malaria
by: Leonardo, L, et al.
Published: (2022)